These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34598656)

  • 41. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
    Leslie WD; Peterdy AE; Dupont JO
    J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radioactive iodine ablation therapy: a viable option in the management of Graves' disease in Nigeria.
    Adedapo KS; Fadiji IO; Orunmuyi AT; Onimode Y; Osifo BO
    Afr J Med Med Sci; 2012 Dec; 41 Suppl():193-6. PubMed ID: 23678656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
    Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
    Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid.
    Schiavo M; Bagnara MC; Calamia I; Bossert I; Ceresola E; Massaro F; Giusti M; Pilot A; Pesce G; Caputo M; Bagnasco M
    J Endocrinol Invest; 2011 Mar; 34(3):201-5. PubMed ID: 21164277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study.
    Peters H; Fischer C; Bogner U; Reiners C; Schleusener H
    Eur J Clin Invest; 1996 Jan; 26(1):59-63. PubMed ID: 8682157
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Nucl Med Commun; 2006 May; 27(5):439-46. PubMed ID: 16609355
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
    Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
    J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up studies on iodine-131 treatment of hyperthyroid Graves' disease based on the measurement of thyroid volume by ultrasonography.
    Tsuruta M; Nagayama Y; Yokoyama N; Izumi M; Nagataki S
    Ann Nucl Med; 1993 Aug; 7(3):193-7. PubMed ID: 8217496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discriminant factors affecting early outcome of radioiodine treatment for Graves' disease.
    Kung AW; Choi P; Lam KS; Pun KK; Wang C; Yeung RT
    Clin Radiol; 1990 Jul; 42(1):52-4. PubMed ID: 2390837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Planning of 131I therapy for graves disease based on the radiation dose to thyroid follicular cells.
    Eterovic D; Antunovic Z; Markovic V; Grosev D
    J Nucl Med; 2008 Dec; 49(12):2026-30. PubMed ID: 18997041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-dose 131I in treatment of Graves' disease.
    Lowdell CP; Dobbs HJ; Spathis GS; McCready VR; Cosgrove DO; Harmer CL
    J R Soc Med; 1985 Mar; 78(3):197-202. PubMed ID: 3838347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improving treatment outcomes for Graves' disease patients with inactive forms of Graves' orbitopathy through an increased dose of radioiodine therapy.
    Gosmann J; Willms D; Bell E; Schreckenberger M; Willms A
    Nuklearmedizin; 2020 Jun; 59(3):260-268. PubMed ID: 32403138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
    Haase A; Bähre M; Lauer I; Meller B; Richter E
    Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
    Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
    J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.